(PRWEB) March 21, 2013
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will present at a program titled “New Updates in Drug Formulation and Bioavailability” on April 9, 2013, organized jointly by Medicon Valley Alliance, KemiVärlden Biotech and Patheon.
A presentation “Solubility and Bioavailability Enhancement for Poorly Soluble Drugs” will be given by Anil Kane, Executive Director, Global Formulation Sciences, Patheon Inc. on Tuesday, April 9, 2013 at 1:35 p.m. Central European Time. For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.
Patheon representatives will also be available to meet during the program, showcasing several of Patheon’s key service offerings, including SoluPath™ - an innovative and cost-effective service used to identify an optimal drug delivery system for compounds with poor bioavailability. In a recent case study, SoluPath™ improved bioavailability by four times in just three months. Learn more by visiting the company’s website at http://www.patheon.com/Services/UniqueSolutions/SoluPath.aspx.
Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.
Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 18 locations, including 14 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.